2 results about "Imatinib" patented technology

The application discloses a method for determining the concentration of sofosbuvir in blood plasma and screening a non-isotope labeled internal standard, wherein anlotinib, imatinib, olaparib, osimertinib and pralsetinib are used as internal standards, quantitative analysis is performed by combining LC-MS / MS with protein precipitation pretreatment. The internal standard screening method is screened from candidate compounds by systematically evaluating four dimensions of protein precipitation compatibility, matrix effect, detection stability and extraction recovery, and an internal standard consistent with the behavior of the measured substance is screened. The application solves the problem of the lack of commercial isotope internal standards for sofosbuvir, and provides a reliable and efficient detection and internal standard screening scheme.

This invention discloses an electrochemiluminescence aptamer sensor for imatinib detection, its preparation method, and its detection application. Addressing the problems of cumbersome procedures and insufficient sensitivity in existing detection methods, this invention constructs the sensor through the following steps: first, gold is deposited on the surface of a glassy carbon electrode; then, double-stranded DNA, bovine serum albumin, imatinib solutions of different concentrations, and a carboxyl-modified activated signal probe solution are incubated sequentially to obtain a sensor for imatinib detection. This invention also discloses a method for detecting imatinib using this sensor. This method combines the high sensitivity of electrochemiluminescence technology with the high specificity of aptamers, possessing advantages such as high sensitivity, low detection limit, wide linear range, rapid detection, simple operation, and small sample volume. It has been successfully applied to the detection of clinical blood samples taken with imatinib.